Companies / Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc.
Nasdaq: TENXCIK 34956CHAPEL HILL, NC
Financials · FY2025
Ownership
37.4M shares outstanding · as of Jul 28, 2026
Ownership
| Insiders | 0.03% | 10,000 |
| Institutions | 36.21% | 13,552,485 |
| Public float | 63.76% | 23,861,432 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 9
View all →| Insider | % of shares | Shares |
|---|---|---|
Staab Thomas R IIChief Financial Officer | 0.03% | 10,000 |
Almenoff June SherieDirector | — | — |
Christopher Thomas GiordanoCEOCEO · Director | — | — |
Davidson Michael H.Director | — | — |
Doogan DeclanDirector | — | — |
Hunter RobynDirector | — | — |
McGauley ThomasInterim CFO | — | — |
Proehl Gerald TDirector | — | — |
Rich StuartChief Medical Officer · Director | — | — |
Institutional holders 55
View all →| Holder | Value | % of shares |
|---|---|---|
| $29.07M | 4.85% | |
| $25.14M | 4.62% | |
| $23.15M | 3.87% | |
| $11.80M | 2.59% | |
| $8.64M | 1.44% | |
| $8.54M | 1.43% | |
| $7.43M | 1.36% | |
| $7.27M | 1.59% | |
| $6.38M | 1.07% | |
| $5.64M | 0.94% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Add | Common stock | $26.40M | +1.6M +989.29% | 1,815,474 4.85% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $24.90M | +1.7M +10238.57% | 1,727,988 4.62% of shares | medium |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | Add | Common stock | $16.13M | +1.0M +229.68% | 1,447,782 3.87% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | New | Common stock | $7.43M | +511K | 510,814 1.36% of shares | medium |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | Add | Common stock | $7.30M | +457K +548.15% | 540,126 1.44% of shares | medium |
| Q1 2026 as of | TD Asset Management Inc 13F manager | New | Common stock | $6.38M | +399K | 399,184 1.07% of shares | medium |
| Q1 2026 as of | Great Point Partners, LLC 13F manager | New | Common stock | $5.23M | +327K | 327,307 0.87% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common stock | $3.70M | +231K +76.51% | 533,889 1.43% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Perceptive Advisors LLC | Passive13G/A | — |
| RTW Investments, LP | Passive13G/A | — |
| Point72 Asset Management, L.P. | Passive13G/A | — |
| Venrock Healthcare Capital Partners III, L.P. | Passive13G/A | — |
| Logos Global Management LP | Passive13G | — |
| Lind Global Fund II LP | Passive13G/A | — |
| Dellora Investments Master Fund LP | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TENX | — | 88032L605 |